Fresenius Medical Care Sees U.S. Plans for Kidney Disease as Positive
Browser Upgrade Recommended: Our website has detected that you are using a version of Internet Explorer that will prevent you from accessing certain features on FMCNA.com. We strongly recommend that you use a different browser to optimize your viewing experience. Supported browsers include Chrome, Edge, Firefox, and Safari.
We are actively monitoring the novel coronavirus (COVID-19) pandemic. Learn About the steps that we are taking to protect our patients, employees, physicians, and partners. If you are a patient with questions or concerns, please find additional information at FreseniusKidneyCare.com and AzuraVascularCare.com
Success! The link has been copied to your clipboard.
The unmatched breadth and depth of our clinical research plays an important role in advancing the scientific understanding of renal and chronic disease care and demonstrates our commitment to improving the lives of our patients. Our research endeavors draw on the strength of the FMCNA global research footprint, and are a distinct competitive advantage in our ability to innovate the future of integrated renal care.”
– Dr. Frank Maddux, FMCNA Chief Medical Officer and Executive Vice President for Clinical and Scientific Affairs
Of the 66 abstracts to be presented from Fresenius Medical Care globally, 56 originate from Fresenius Medical Care North America, with an additional 10 abstracts presented as Fresenius Medical Care sponsored research. Overall, 76 abstracts associated with Fresenius Medical Care will be displayed at the ASN 2016 Kidney Week symposium.
These presentations are efforts aimed to enhance quality of life and outcomes of care delivered to patients with chronic kidney diseases and fall into eight categories:
Highlights of key presentations at the ASN Kidney Week Meeting involving the organization’s staff include:
FMCNA research is an ongoing endeavor throughout the year: in the first quarter of 2016 alone, FMCNA had 20 published journal articles, and since 2015, its research has included more than 125 abstracts accepted, involving the contributions of more than 1,200 FMCNA staff members. As the largest and most comprehensive integrated renal care company in North America, FMCNA is unmatched in its ability to gather and analyze immense amounts of patient data from within the company’s own care ecosystem.
With the nature of dialysis care allowing FMCNA to collect large amounts of patient data during routine treatments, the company has collected data on more than 1 million patients, including data on more than 250 million dialysis treatments, more than 1 billion medication administrations and over 1 billion laboratory results.
“Research, data and analytics are the innovation engines that inform every aspect of our direct patient care, quality improvement programs, coordinated care delivery and care integration,” Maddux said. “The researchers at Fresenius Medical Care are helping to create the very roadmap that will continue to drive the future of renal care.”
About Fresenius Medical Care North America
Fresenius Medical Care North America is the premier health care company focused on providing the highest quality care to people with renal and other chronic conditions. Through its industry-leading network of dialysis facilities, outpatient cardiac and vascular labs, and urgent care centers, as well as the country’s largest practice of hospitalist and post-acute providers, Fresenius Medical Care provides coordinated health care services at pivotal care points for hundreds of thousands of chronically ill customers throughout the continent. As the world’s largest fully integrated renal company, it offers specialty pharmacy and laboratory services, and manufactures and distributes the most comprehensive line of dialysis equipment, disposable products, and renal pharmaceuticals. For more information, visit the FMCNA website at www.fmcna.com. For information about patient services, visit www.freseniuskidneycare.com.
About the American Society of Nephrology
Founded in 1966, the American Society of Nephrology (ASN) is the world’s largest professional society devoted to the study of kidney disease. With 15,000 physician and scientist members, ASN leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients. ASN also informs policymakers about issues of importance
to kidney doctors and their patients. ASN funds research, and through its world-renowned meetings and first-class publications, disseminates information and educational tools that empower physicians. For more information about the society, visit www.asn-online.org/.